At the time of writing, Acrivon Therapeutics Inc [ACRV] stock is trading at $1.98, up 5.88%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACRV shares have gain 13.14% over the last week, with a monthly amount drifted -18.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $16 on the stock. Ladenburg Thalmann downgraded its rating to a Neutral. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $14 as its price target on March 01, 2024. In a note dated October 05, 2023, Maxim Group initiated a Buy rating.
For the past year, the stock price of Acrivon Therapeutics Inc fluctuated between $1.05 and $8.00. Currently, Wall Street analysts expect the stock to reach $21.83 within the next 12 months. Acrivon Therapeutics Inc [NASDAQ: ACRV] shares were valued at $1.98 at the most recent close of the market. An investor can expect a potential return of 1002.53% based on the average ACRV price forecast.
Analyzing the ACRV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.54 and Total Capital is -0.68. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Acrivon Therapeutics Inc [NASDAQ:ACRV] has a current ratio of 8.75. On the other hand, the Quick Ratio is 8.75, and the Cash Ratio is 2.38.
Transactions by insiders
Recent insider trading involved Blume-Jensen Peter, President and CEO, that happened on Jan 14 ’26 when 49000.0 shares were purchased. Chief Financial Officer, Levy Adam D. completed a deal on Jan 14 ’26 to buy 8832.0 shares. Meanwhile, Chief Operating Officer Devroe Eric bought 10000.0 shares on Jan 13 ’26.
